News

FDA moves to alert physicians, public to counterfeit Botox


 

FROM THE FDA

References

Counterfeit Botox has been found in the United States and could be in offices and clinics across the country, the Food and Drug Administration announced on April 17.

Authentic vial Courtesy Food and Drug Administration

Authentic vial

The counterfeit Botox “may have been sold” to medical clinics and physicians’ offices; the source is an unlicensed supplier that is not authorized to ship or distribute drug products in this country. “The counterfeit products are considered unsafe and should not be used. FDA cannot confirm that the manufacture, quality, storage, and handling of these suspect products follow U.S. standards,” according to the FDA statement, which notes that the agency is not aware of any adverse events resulting from the use of the counterfeit product.

“Currently, there is no indication that Allergan’s FDA-approved version is at risk, and the genuine product should be considered safe and effective for its intended and approved use,” the FDA statement said.

Features that can help identify the counterfeit product include a missing lot number on the vial. And instead of “OnabotulinumtoxinA” on the vial and outer carton (which is printed on the label and outer carton of the FDA-approved Botox manufactured by Allergan), the counterfeit product has “Botulinum Toxin Type A” on the outer carton and vial.

Counterfeit vial Courtesy Food and Drug Administration

Counterfeit vial

The counterfeit product also does not have anything written after the “LOT: MFG: EXP:” section of the outer carton.

The Allergan website also has information on how to identify counterfeit Botox, which includes a list of authorized distributors. In addition, a list of the state agencies that license wholesale prescription drug distributors is available on the FDA’s website.

The FDA is asking anybody who is aware of any Botox product thought to be counterfeit to contact the agency’s Office of Criminal Investigations (OCI) at 800-551-3989, www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm, or by e-mail at DrugSupplyChainIntegrity@fda.hhs.gov.

Adverse events thought to be related to counterfeit Botox should be reported to the FDA’s MedWatch program at800-332-1088, or https://www.accessdata.fda.gov/scripts/medwatch/.

emechcatie@frontlinemedcom.com

Recommended Reading

VIDEO: Finesse is key to avoiding exfoliation mistakes
MDedge Dermatology
Fellowships After Dermatology Residency: The Traditional and Beyond
MDedge Dermatology
Cosmetic Corner: Dermatologists Weigh in on Antiaging Moisturizers
MDedge Dermatology
Minimally invasive cosmetic procedures climb by 20% since 2010
MDedge Dermatology
Rapidly Recurring Keratoacanthoma
MDedge Dermatology
Skin Rejuvenation With Fat Grafting and Stem Cells
MDedge Dermatology
Plant-based supplement safely protects against UV radiation
MDedge Dermatology
Cosmetic procedures in pregnancy
MDedge Dermatology
Teenage tattoos are most often regretted
MDedge Dermatology
Plantago major
MDedge Dermatology